Chief Executive Officer & Founder
Lisa has been a pioneer in the biotech/emerging pharmaceutical industry for 20 years. She is founder and CEO of Napo Pharmaceuticals, which brings proprietary products to the global marketplace through local partnerships. Napo embraces the “triple bottom line” goals of enhancing financial return by addressing global health needs in its development strategy and environmental sustainability in sourcing its lead product, which is harvested from rain forest areas.
Prior to founding Napo, she founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company, in 1989. As CEO, she has raised >$250 million (including leading two IPOs). 1987 to 1989 Ms. Conte was a Vice President at Technology Funding, Inc., a venture capital firm. From 1985 to 1987 she conducted risk and strategy audits for start-up companies at Strategic Decisions Group. Lisa received her AB in Biochemistry from Dartmouth College, her MS in Physiology/Pharmacology from the University of California at San Diego and her MBA from the Amos Tuck School, Dartmouth College. She is the recipient of several entrepreneurship awards, including the 1994 E&Y Entrepreneur of the Year Award, has sat on several industry and academic boards, and was a nominee for the 2009 BIO Humanitarian Award.
Roger Waltzman, MD, MBA
President & Chief Medical Officer
Roger is a Board-certified Medical Oncologist with over 20 years’ experience supervising the delivery of complex oncology patient care and palliative medicine in teaching hospitals and developing new drugs in oncology and in malaria at large pharma. Prior to joining Napo, Roger was the Global Program Head responsible for all early and late-stage development activities of antimalarials at Novartis, including Coartem and two compounds in Phase 2 development, including generating a collaboration agreement with Medicines for Malaria Venture and the Bill and Melinda Gates Foundation. Previously, Roger was responsible for Global Clinical Development activities for several oncology compounds including the successful NDA filing of Jakavi, Tasigna, and an sNDA for Glivec. For nearly 12 years, Roger worked as a clinical medical oncologist and clinical researcher at Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, and Saint Vincents Cancer Center, all in New York. He held academic positions as Assistant Professor in the Department of Medicine at Mount Sinai School of Medicine and New York Medical College. Roger received his undergraduate degree magna cum laude from Brown University in Providence, RI with honors in American Literature. He also received his medical degree from Brown University School of Medicine and completed his internship and residency at Harvard’s Beth Israel Hospital in Boston, MA. He completed his fellowship at Memorial Sloan-Kettering Cancer Center in hematology and oncology. He graduated with an MBA from Columbia University in New York.
Chief Financial Officer
Mr. Thompson joined Napo Pharmaceuticals as Vice President Finance and Chief Financial Officer in June 2002. From April 2001 to April 2002, he was the Chief Financial Officer of Celestry Design Technologies, Inc., a developer of design automation software. During his tenure at Celestry, that company grew from 70 employees to over 130 employees and established five offshore sales and R&D subsidiaries. Prior to Celestry, Mr. Thompson was in investment banking with Sutro & Co. Incorporated and Roth Capital Partners. Mr. Thompson holds a BBA in Finance from the University of Oklahoma and is a Certified Public Accountant.
Steven King, PhD
Executive Vice President of Sustainable Supply, Ethnobotanical Research & Intellectual Property
Dr. King has served as our Executive Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property since March 2014. From 2002 to 2014, Dr. King served as the Senior Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property at Napo Pharmaceuticals, Inc. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds a PhD in Biology from the Institute of Economic Botany of the New York Botanical Garden and an MS in Biology from the City University of New York.
Katie MacFarlane, PharmD
Senior Vice President, Commercial Development
Katie MacFarlane is an experienced pharmaceutical executive with over 25 years in the industry, including senior level roles in drug development, marketing, and sales management. Katie played a key role in the launch of many pharmaceutical brands, most notably Lipitor®, Celexa®, and Loestrin® 24. Katie’s GI experience includes clinical research in IBS (Librax®) and obesity (Xenical®), as well as consultation on Amitiza® (constipation and IBS) and crofelemer. Katie has held senior roles including Chief Commercial Officer of Agile Therapeutics, Vice President of Women’s Health and New Product Planning at Warner Chilcott, and Sr. Director of Marketing at Parke-Davis/Warner-Lambert.
Katie received her BS and PharmD degrees from Purdue University and completed a Postdoctoral Fellowship with Rutgers University and Hoffmann-LaRoche. She was named a Distinguished Alumna in 1999 and was awarded the Eaton Entrepreneur of the Year in 2012 by the Purdue University School of Pharmacy. Katie currently serves on the Purdue Pharmacy Dean’s Advisory Council, is a Founding Member and Advisor to IPhO, and serves as an Affiliate Faculty member in the Department of Pharmacy Practice at Purdue University. She is a member of the Board of Directors of RespireRx Pharmaceuticals and of INMED Partnerships for Children.
Brian Zorn, PharmD
Senior Vice President, Marketing & Sales
Brian Zorn has 23 years experience in pharmaceutical marketing, advertising, and sales. He held marketing resposibilities for key brands such as Accupril®, Omnicef®, Neurontin®, Bextra®, Menopur®, Euflexxa®, Endometrin®, PreCrea®, and PreLipid®. He was the General Manager at Trio Advertising, and at Parke-Davis, he was the Senior-Director of Marketing as well as a New Product Planner.